Welcome to our dedicated page for Prestige Consmr Healthcare news (Ticker: PBH), a resource for investors and traders seeking the latest updates and insights on Prestige Consmr Healthcare stock.
Prestige Consumer Healthcare Inc (NYSE: PBH) maintains leadership in over-the-counter healthcare through trusted brands like Clear Eyes and Summer’s Eve. This news hub provides investors and industry professionals with essential updates on corporate developments, regulatory milestones, and market strategies.
Access comprehensive coverage of PBH’s operational updates including earnings announcements, product innovations, and supply chain initiatives. Our curated news collection offers context for understanding the company’s position in competitive OTC markets across North America and international regions.
Key updates feature strategic partnerships, quality assurance developments, and responses to evolving consumer health trends. The resource serves as a centralized reference for tracking PBH’s commitment to product stewardship and operational efficiency in dynamic healthcare markets.
Bookmark this page for streamlined access to press releases and analysis on PBH’s market navigation. Regular updates ensure stakeholders maintain current awareness of corporate initiatives impacting long-term value creation in consumer healthcare.
Prestige Consumer Healthcare (NYSE:PBH) has announced it will release its fiscal 2025 fourth quarter and year-end earnings results on Thursday, May 8, 2025, before market opening. The company will host a conference call to discuss the results at 8:30 a.m. ET on the same day.
Investors can access the live Internet webcast through the Investor Relations page of prestigeconsumerhealthcare.com. Phone participation is available through pre-registration, with participants recommended to join 10 minutes before the event. A replay of the conference call will be accessible for approximately one week following the live call via the company's Investor Relations page.
Prestige Consumer Healthcare (NYSE:PBH) reported strong Q3 fiscal 2025 results with revenue reaching $290.3 million, up 2.7% year-over-year. The company achieved record quarterly sales and earnings, with diluted EPS increasing approximately 15% to $1.22.
The performance was driven by strong International business growth, particularly the Hydralyte brand, and sequential improvement in Clear Eyes revenues. The company's net income for Q3 increased to $61.0 million from $53.0 million in the prior year.
The company reduced its leverage to 2.5x and generated strong free cash flow of $63.5 million in Q3. Based on the strong performance, management raised its full-year fiscal 2025 earnings outlook to approximately $4.50 per share, while maintaining revenue guidance of $1,128 to $1,132 million with organic growth of approximately 1%.
Prestige Consumer Healthcare (NYSE:PBH) has announced two important upcoming events. First, the company will release its fiscal 2025 third quarter earnings on Thursday, February 6, 2025, before market opening, followed by a conference call at 8:30 a.m. ET. Investors can join the webcast through the company's Investor Relations webpage or register for phone participation.
Additionally, PBH will participate in a fireside chat at the 27th annual ICR Conference in Orlando, FL on Tuesday, January 14th, at 11:30 a.m. ET. Both events will be accessible via webcast on the company's website, with replays available afterward.
Prestige Consumer Healthcare (NYSE: PBH) has expanded the role of Chief Financial Officer Christine Sacco to include Chief Operating Officer responsibilities, effective immediately. In this enhanced role, Ms. Sacco will oversee the Company's supply chain along with her existing CFO duties. She will continue to report to CEO Ron Lombardi. Lombardi highlighted Sacco's strategic leadership and deep understanding of the business, which have been instrumental in the company's growth over her 8-year tenure as CFO.
Ms. Sacco, a seasoned executive with over 27 years of experience in the consumer products and specialty pharma sectors, has been the CFO since 2016. Her tenure has seen significant contributions to Prestige's strategic transformation and financial success, including strong sales, earnings, and cash flow growth. This expanded role aims to enhance the execution of strategic initiatives and drive operational excellence, positioning Prestige for further organic and M&A growth.
Prestige Consumer Healthcare reported Q2 fiscal 2025 results with revenue of $283.8 million, down 0.9% year-over-year. Diluted EPS increased 2% to $1.09. Net cash from operations grew 13% to $125 million in first six months. The company reduced debt by $75 million and repurchased $38 million in shares year-to-date.
Q2 performance was driven by strong growth in International and Canadian businesses, offsetting Clear Eyes® supply constraints. The company reaffirmed its fiscal 2025 outlook with revenue guidance of $1,125-$1,140 million, organic revenue growth of approximately 1%, and adjusted EPS of $4.40-$4.46.
Prestige Consumer Healthcare Inc. (NYSE:PBH) has announced the release date for its fiscal 2025 second quarter earnings. The company will issue the earnings release on Thursday, November 7, 2024, before the market opens. Following the release, Prestige Consumer Healthcare will host a conference call at 8:30 a.m. ET to discuss the results.
Investors and interested parties can participate in the earnings discussion through two methods:
- A live Internet webcast accessible from the Investor Relations page of www.prestigeconsumerhealthcare.com
- A conference call via phone, with registration required to receive dial-in details and a unique pin
Participants are advised to join 10 minutes prior to the event start. A replay of the conference call will be available for approximately one week on the company's Investor Relations page.
Prestige Consumer Healthcare (NYSE:PBH) has announced its participation in the Barclays Global Consumer Staples Conference on Thursday, September 5, 2024, at 2:15 p.m. ET. The company will present at this significant industry event, offering insights into its operations and strategy.
Interested parties can access a live webcast of the presentation through the company's official website under the 'Investors' section and 'Events and Presentations' tab. For those unable to attend the live event, a replay option will be available on the company's website following the presentation. This announcement highlights Prestige Consumer Healthcare's commitment to investor relations and transparency in its business operations.
Prestige Consumer Healthcare Inc. (NYSE:PBH) reported Q1 fiscal 2025 results with revenue of $267.1 million, down 4.4% year-over-year but ahead of expectations. EPS was $0.98 and adjusted EPS was $0.90, compared to $1.06 in the prior year. Cash from operations increased 13.9% to $54.8 million. The company reduced debt by $35 million and repurchased $26 million in shares.
Key highlights:
- North American OTC Healthcare segment revenue decreased 5.6% to $232.3 million
- International OTC Healthcare segment revenue increased 5.0% to $34.8 million
- Free cash flow increased to $53.6 million
- Net debt position of approximately $1.1 billion with a leverage ratio of 2.8x
The company reaffirmed its full-year fiscal 2025 outlook, expecting revenue of $1,125 to $1,140 million, organic revenue growth of approximately 1%, and adjusted EPS of $4.40 to $4.46.
Prestige Consumer Healthcare announced its fiscal 2025 first quarter earnings release will be issued on August 8, 2024, before the market opens.
The company will host a conference call to discuss the results at 8:30 a.m. ET the same day. Participants can join the live Internet webcast via the Investor Relations page on the company's website. Phone participants need to register to receive dial-in details and a unique pin. It is recommended to join the call 10 minutes early. A replay of the conference call will be available for a week on the Investor Relations page.
Prestige Consumer Healthcare (NYSE:PBH) will present at the Oppenheimer Annual Consumer Growth and E-Commerce Conference on June 10, 2024, at 1:30 p.m. ET. Interested parties can access a live webcast of the event via the company's website under the 'Investors' section or use the provided link. A replay will be available for those unable to attend the live session.
